Location of CD39+ T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer

被引:6
|
作者
Koppensteiner, Lilian [1 ]
Mathieson, Layla [1 ]
Pattle, Samuel [2 ]
Dorward, David A. [2 ]
O'Connor, Richard [1 ]
Akram, Ahsan R. [1 ,3 ]
机构
[1] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Scotland
[2] Royal Infirm, Dept Pathol, Edinburgh, Scotland
[3] Univ Edinburgh, Inst Genet & Mol Med, Canc Res UK Edinburgh Ctr, Edinburgh, Scotland
关键词
tumor biomarkers; biomarkers; tumor; immune checkpoint inhibitors; lung neoplasms; non-small cell lung cancer; TERTIARY LYMPHOID STRUCTURES; STROMAL CELLS; RESPONSES;
D O I
10.1136/jitc-2023-006770
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose An improved mechanistic understanding of immunosuppressive pathways in non-small cell lung cancer (NSCLC) is important to develop novel diagnostic and therapeutic approaches. Here, we investigate the prognostic significance of the ectonucleotidases CD39 and CD73 in NSCLC.Experimental design The expression and localization of CD39, CD73 and CD103 was digitally quantified in a cohort of 162 early treatment naive NSCLC patients using multiplex-immunofluorescence and related to patient outcome. Expression among different cell-populations was assessed via flow cytometry. Targeted RNA-Seq was performed on CD4(+) and CD8(+) T cells from digested NSCLC tumor tissue and single-cell RNA-Seq data was analyzed to investigate the functional significance of CD39(+) T cell populations.Results We demonstrate that flow cytometry of early untreated NSCLC patients shows an upregulation of CD39 expression in the tumor tissue among natural killer (NK) cells, fibroblasts and T cells. CD73 expression is mainly found among fibroblasts and Epcam+cells in the tumor tissue. Multiplex Immunofluorescence in a cohort of 162 early untreated NSCLC patients demonstrates that CD39 expression is mainly localized in the tumor stroma while CD73 expression is equally distributed between tumor nest and stroma, and high expression of CD39 and CD73 in the tumor stroma is associated with poor recurrence-free survival (RFS) at 5 years. Additionally, we find that CD8+T cells located in the tumor nest express CD103 and the density of CD39+CD103+CD8+ T cells in the tumor nest predicts improved RFS at 5 years. Targeted RNA-Seq shows that the tumor microenvironment of NSCLC upregulates regulatory pathways in CD4+ T cells and exhaustion in CD8(+) T cells, and analysis of a single cell RNA sequencing dataset shows that CD39(+)CD4(+) cells are enriched in Treg signature gene-sets, and CD39(+)CD103(+)cytotoxic T lymphocyte show gene signatures indicative of an exhausted cytotoxic phenotype with upregulated expression of CXCL13.Conclusions Knowledge of patterns of distribution and location are required to understand the prognostic impact of CD39(+) T cell populations in NSCLC. This study provides an improved understanding of spatial and functional characteristics of CD39(+) T cells and their significance to patient outcome.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Characterization of different CTC subpopulations in non-small cell lung cancer
    Annkathrin Hanssen
    Jenny Wagner
    Tobias M. Gorges
    Aline Taenzer
    Faik G. Uzunoglu
    Christiane Driemel
    Nikolas H. Stoecklein
    Wolfram T. Knoefel
    Sebastian Angenendt
    Siegfried Hauch
    Djordje Atanackovic
    Sonja Loges
    Sabine Riethdorf
    Klaus Pantel
    Harriet Wikman
    Scientific Reports, 6
  • [2] Characterization of different CTC subpopulations in non-small cell lung cancer
    Hanssen, Annkathrin
    Wagner, Jenny
    Gorges, Tobias M.
    Taenzer, Aline
    Uzunoglu, Faik G.
    Driemel, Christiane
    Stoecklein, Nikolas H.
    Knoefel, Wolfram T.
    Angenendt, Sebastian
    Hauch, Siegfried
    Atanackovic, Djordje
    Loges, Sonja
    Riethdorf, Sabine
    Pantel, Klaus
    Wikman, Harriet
    SCIENTIFIC REPORTS, 2016, 6
  • [3] Disparities in Non-Small Cell Lung Cancer Outcomes
    Yamani, F.
    Zhao, W.
    Monde, R-A
    Reis, I.
    Hu, J.
    Lally, B.
    MODERN PATHOLOGY, 2014, 27 : 499A - 499A
  • [4] Disparities in Non-Small Cell Lung Cancer Outcomes
    Yamani, F.
    Zhao, W.
    Monde, R-A
    Reis, I.
    Hu, J.
    Lally, B.
    LABORATORY INVESTIGATION, 2014, 94 : 499A - 499A
  • [5] Retinoblastoma mutation to predict poor outcomes in non-small cell lung cancer (NSCLC).
    Bhateja, Priyanka
    Wildey, Gary
    Fu, Pingfu
    Lipka, Mary Beth
    Ardeshir-Larijani, Fatemeh
    Sharma, Neelesh
    Dowlati, Afshin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer
    Coe, B. P.
    Lockwood, W. W.
    Girard, L.
    Chari, R.
    MacAulay, C.
    Lam, S.
    Gazdar, A. F.
    Minna, J. D.
    Lam, W. L.
    BRITISH JOURNAL OF CANCER, 2006, 94 (12) : 1927 - 1935
  • [7] Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer
    B P Coe
    W W Lockwood
    L Girard
    R Chari
    C MacAulay
    S Lam
    A F Gazdar
    J D Minna
    W L Lam
    British Journal of Cancer, 2006, 94 : 1927 - 1935
  • [8] Radiomic Signature to Predict Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer
    Minatta, J. N.
    Deza, D.
    Aineseder, M.
    Nunez, M. Mestas
    Mosquera, C.
    Lupinacci, L.
    Benitez, S.
    Seehaus, A.
    Luna, D.
    Beresnak, A.
    Diaz, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1166 - S1166
  • [9] Pneumonectomy for Non-Small Cell Lung Cancer: Outcomes Analysis
    Kalathiya, Rohan J.
    Saha, Sibu P.
    SOUTHERN MEDICAL JOURNAL, 2012, 105 (07) : 350 - 354
  • [10] Reirradiation for Locoregionally Recurrent Lung Cancer Outcomes in Small Cell and Non-Small Cell Lung Carcinoma
    Kruser, Tim J.
    McCabe, Bradley P.
    Mehta, Minesh P.
    Khuntia, Deepak
    Campbell, Toby C.
    Geye, Heather M.
    Cannon, George M.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (01): : 70 - 76